|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Centers for Disease Control and Prevention;
2 Saint Louis University School of Medicine;
3 The EMMES Corporation
4 E-mail: iad7{at}cdc.gov
The search for a 'third' generation smallpox vaccine has resulted in the development and characterization of several vaccine candidates. A significant barrier in acceptance is the absence of challenge models showing induction of correlates of protective immunity against Variola virus. In this light, virus neutralization provides one of few experimental methods to show specific in vivo activity of vaccines against Variola virus. Here we provide characterization of the ability of a Modified Vaccinia Ankara (MVA) vaccine to induce variola neutralizing antibodies, and we provide comparison to that elicited by standard Dryvax vaccination.
Received 23 January 2009;
accepted 28 March 2009.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |